← Human Trials & Peer-Reviewed Studies
Intrauterine Human Chorionic Gonadotropin at the Time of Embryo Transfer
Plain-language guide to NCT01643993: not phased randomized trial of hCG (human chorionic gonadotropin), 300 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT01643993
- Phase
- not phased
- Status
- completed
- Start
- 2012-05
- Completion (planned or actual)
- 2014-01
- Participants
- 300 (actual)
- Design
- randomized, open label (everyone knows who gets what), treatment
- Conditions studied
- Control Media Only; Study hCG and Media
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
In this not phased trial, researchers set out to test hCG (human chorionic gonadotropin).
However, in IVF cycles, the embryos have limited time to secrete hCG before implantation must occur because embryos are placed into the uterus rather than traveling there from the fallopian tubes.
It had two arms (groups): hCG at Time of Embryo Transfer (experimental) and Control (other).
The registry classes the interventions as other.
Who Took Part
300 actual participants took part.
It was open to women only aged from 18 years up to 43 years.
Healthy volunteers could join, not only people with the condition.
Examples of who could join: All patients 43 years old or under undergoing fresh or frozen IVF cycles are eligible to participate.
The full record lists 1 inclusion and 2 exclusion criteria; among the exclusions: patients greater than 43 years old; patinets currently participating in any other research studies.
How the Study Was Run
The set-up was randomized, parallel-group and open-label.
Random assignment meant chance, not the researchers, decided who got hCG (human chorionic gonadotropin) and who got the comparison, which limits bias.
The hCG (human chorionic gonadotropin) group and the comparison group ran side by side rather than switching.
Nothing was hidden in this open-label hCG (human chorionic gonadotropin) study: the participants and staff both knew the treatment.
It started in 2012-05 with completion listed for 2014-01.
It ran at 2 sites in United States (2).
Its stated primary purpose is treatment.
What Was Measured
Primary outcome: Sustained implantation rate (time frame: 12 weeks).
It also tracked 1 secondary outcome, for example Ongoing pregnancy rate.
What This Means in Plain Language
Put simply, this is a not phased, randomized trial of hCG (human chorionic gonadotropin) in 300 people.
The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the hCG (human chorionic gonadotropin) compound page, all human trials.
Our Notes on the Compound
hCG (human chorionic gonadotropin): An LH analog that drives Leydig-cell testosterone production.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.